Zydus Lifesciences inks licensing agreement with Dr. Reddy’s Laboratories

29 Jun 2024 Evaluate

Zydus Lifesciences has executed a licensing agreement with Dr. Reddy’s Laboratories to co-market Pertuzumab biosimilar in India. Pertuzumab is a critical treatment for HER2 positive breast cancer patients. The biosimilar has been developed in-house by the research team at the Zydus Research Centre (ZRC). 

Under the terms of this agreement, Dr. Reddy’s will receive semi-exclusive rights from Zydus to co-market the product in India. The product will be marketed by Zydus under the brand name Sigrima. Dr. Reddy’s will market it under the brand name Womab. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

910.05 -4.60 (-0.50%)
01-Jan-2026 10:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1714.40
Dr. Reddys Lab 1254.60
Cipla 1504.25
Zydus Lifesciences 910.05
Lupin 2084.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×